SecBot SecBot
Biotech Drug Report Generated Aug 27, 2026

iDose TREX

GKOS·GLAUKOS Corp
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2b/3
Time to market
Unknown; Phase 2b/3 trials typically take 2-4 years to complete, so potential approval would likely be 2028-2030 at earliest, assuming positive data.
Why 4/10
No specific hard, dated catalyst (PDUFA or pivotal readout date) is scheduled within the next ~12 months. iDose TREX is a mid-stage (Phase 2b/3) program at a company with an already-approved commercial product (iDose TR) and other pipeline assets, so it is not a near-term binary event for the stock.
Actionable Insight NEUTRAL

Monitor for interim or topline data readouts from the Phase 2b/3 program, which could serve as a catalyst. The next meaningful update may come at a major ophthalmology conference. Meanwhile, iDose TR commercial adoption trends and quarterly earnings are the primary near-term drivers for GKOS stock.

Price Chart

Loading chart...

Executive Summary

iDose TREX is Glaukos' next-generation sustained-release travoprost intracameral implant for glaucoma, designed with nearly double the drug capacity of the already-FDA-approved iDose TR. Glaukos commenced a Phase 2b/3 clinical program in January 2025, and early data from a 10-patient study presented at AGS 2026 showed positive IOP reduction. As a mid-stage pipeline asset at a company with an approved commercial product (iDose TR) and other programs, iDose TREX is not a near-term binary catalyst. The stock trades near its 52-week high with strong analyst support (Strong Buy consensus, ~8% implied upside to mean target), but insider selling and mixed institutional signals warrant caution.

How It Works

iDose TREX is a tiny implant placed inside the eye that continuously releases travoprost, a prostaglandin analog drug that lowers intraocular pressure (eye pressure) in glaucoma patients. It is designed to provide long-duration pressure control from a single administration, reducing the need for daily eye drops. The 'TREX' version holds nearly twice the drug as the already-approved iDose TR, potentially extending the duration of effect.

Trial Status

Glaukos commenced a Phase 2b/3 clinical program for iDose TREX in January 2025. Early data from a 10-patient study presented at the American Glaucoma Society (AGS) meeting in March 2026 showed double-digit IOP reduction. The Phase 2b/3 program is designed to support eventual FDA approval, building on the safety and efficacy data from the first-generation iDose TR product.

The Two-Sided Case

▲ Bull Case4
iDose TREX has nearly double the drug capacity of the already-approved iDose TR, potentially offering longer-lasting IOP control and a competitive advantage in the glaucoma implant market.
The first-generation iDose TR is already FDA-approved and commercially launched, providing a clinical and regulatory de-risking pathway for iDose TREX.
Analyst consensus is Strong Buy (18 buy/strong buy vs 2 hold and 1 sell) with a mean price target of $197.15, implying ~8% upside from the current ~$180.57 price.
Strong institutional ownership with BlackRock holding ~$1.33B, Vanguard ~$821M, and multiple funds adding/doubling positions in Q2 2026.
▼ Bear Case5
iDose TREX is still in Phase 2b/3 with no specific topline readout date announced, meaning a potential approval is likely years away (2028-2030 at earliest).
Multiple insiders (President & COO, directors) have been selling shares in recent months, with transactions totaling over $1M at prices around $150-190.
Short interest stands at ~6.70% of outstanding shares (5.21 days to cover), indicating some bearish positioning.
Competition exists from other glaucoma implants (e.g., Bausch + Lomb's Durysta) and traditional eye drops, which could limit iDose TREX's commercial potential.
Several institutional investors trimmed or exited positions in Q2 2026, including Dimensional Fund Advisors (-56%), Susquehanna (-61%), and exits by Capital International Investors and Qube Research.

Upcoming Catalysts

  • Interim or topline data from the Phase 2b/3 clinical program
  • Presentations at major ophthalmology conferences (AAO, AGS)
  • iDose TR commercial adoption and revenue growth updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GLAUKOS Corp 8-K GKOS ·Originating report

Sources · 9

Hover a chip for the title
1 glaukos.com2 investors.glaukos.com3 ophthalmologybreakingnews.com4 businesswire.com5 ophthalmologytimes.com6 glaucomaphysician.net7 synapse.patsnap.com8 ophthalmology360.com9 glaukos.com